Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Harpoon Therapeutics, Inc. | 10%+ Owner | Common Stock | 6.33M | $146M | $23.00 | Jun 2, 2021 | Indirect |
Cullinan Oncology, Inc. | Director | Common Stock | 7.65M | $95.3M | $12.46 | Dec 31, 2021 | Indirect |
iTeos Therapeutics, Inc. | 10%+ Owner | Common Stock | 4.48M | $37.5M | $8.37 | Jan 5, 2022 | Indirect |
Allovir, Inc. | Director, 10%+ Owner | Common Stock | 16.7M | $11.2M | $0.67 | Jul 28, 2022 | By ElevateBio LLC |
Repare Therapeutics Inc. | 10%+ Owner | Common Shares | 3.88M | $9.42M | $2.43 | Jul 12, 2021 | Indirect |
Cullinan Oncology, Inc. | Director | Common Stock | 595K | $7.42M | $12.46 | Dec 21, 2021 | Direct |
Allovir, Inc. | Director, 10%+ Owner | Common Stock | 30.2K | $20.3K | $0.67 | Jul 28, 2022 | Direct |
Cullinan Oncology, Inc. | Director | Stock Option (Right to Buy) | 0 | Dec 21, 2021 | Direct | ||
TCR2 THERAPEUTICS INC. | Director, 10%+ Owner | Common Stock | 0 | $1.72 | Jun 1, 2023 | Indirect | |
TCR2 THERAPEUTICS INC. | Director, 10%+ Owner | Common Stock Warrant (Right to Buy) | 0 | May 22, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TCRR | TCR2 THERAPEUTICS INC. | Jun 1, 2023 | 3 | $0 | 4 | Jun 5, 2023 | Director, 10%+ Owner |
TCRR | TCR2 THERAPEUTICS INC. | May 22, 2023 | 4 | -$1 | 4 | May 24, 2023 | Director, 10%+ Owner |
ALVR | Allovir, Inc. | Jul 28, 2022 | 1 | $15M | 4 | Aug 1, 2022 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Jun 22, 2022 | 1 | $0 | 4 | Jun 23, 2022 | Director |
ALVR | Allovir, Inc. | May 17, 2022 | 1 | $0 | 4 | May 19, 2022 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Jan 4, 2022 | 5 | -$10.5M | 4 | Jan 6, 2022 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Dec 31, 2021 | 3 | $1.51M | 5 | Feb 10, 2023 | Former Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Dec 3, 2021 | 9 | -$2.81M | 4 | Dec 7, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Nov 30, 2021 | 7 | -$4.82M | 4 | Dec 2, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Nov 26, 2021 | 4 | -$1.36M | 4 | Nov 30, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Nov 17, 2021 | 8 | -$4.74M | 4 | Nov 24, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Oct 15, 2021 | 3 | -$785K | 4 | Oct 18, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Oct 12, 2021 | 3 | -$2.58M | 4 | Oct 14, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Oct 7, 2021 | 3 | -$2.37M | 4 | Oct 12, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Oct 1, 2021 | 2 | -$1.25M | 4 | Oct 5, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 28, 2021 | 2 | -$972K | 4 | Sep 30, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 23, 2021 | 4 | -$2.48M | 4 | Sep 27, 2021 | 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 21, 2021 | 2 | -$1.56M | 4 | Sep 23, 2021 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Sep 16, 2021 | 1 | $0 | 4 | Mar 25, 2022 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 16, 2021 | 4 | -$4.33M | 4 | Sep 20, 2021 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Sep 16, 2021 | 2 | -$103K | 4 | Sep 20, 2021 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 14, 2021 | 4 | -$2.12M | 4 | Sep 16, 2021 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Sep 14, 2021 | 4 | -$449K | 4 | Sep 16, 2021 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 9, 2021 | 4 | -$2.73M | 4 | Sep 13, 2021 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Sep 9, 2021 | 6 | -$774K | 4 | Sep 13, 2021 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Sep 7, 2021 | 4 | -$2.07M | 4 | Sep 8, 2021 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Sep 3, 2021 | 6 | -$1.62M | 4 | Sep 8, 2021 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Aug 31, 2021 | 8 | -$816K | 4 | Sep 2, 2021 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Aug 27, 2021 | 4 | -$1.48M | 4 | Aug 31, 2021 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Aug 23, 2021 | 6 | -$3.53M | 4 | Aug 25, 2021 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Aug 11, 2021 | 2 | -$83K | 4 | Aug 12, 2021 | Director, 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jul 9, 2021 | 3 | -$2.08M | 4 | Jul 13, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 28, 2021 | 3 | -$654K | 4 | Jun 30, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 24, 2021 | 2 | -$961K | 4 | Jun 28, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 21, 2021 | 5 | -$1.47M | 4 | Jun 23, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 17, 2021 | 4 | -$1.4M | 4 | Jun 21, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 14, 2021 | 2 | -$207K | 4 | Jun 16, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 8, 2021 | 4 | -$2.09M | 4 | Jun 10, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 3, 2021 | 6 | -$1.86M | 4 | Jun 7, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 28, 2021 | 5 | -$1.19M | 4 | Jun 2, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | May 28, 2021 | 4 | -$1.24M | 4 | Jun 2, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 26, 2021 | 2 | -$347K | 4 | May 27, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | May 25, 2021 | 6 | -$1.27M | 4 | May 27, 2021 | 10%+ Owner |
ALVR | Allovir, Inc. | May 25, 2021 | 1 | $0 | 4 | May 27, 2021 | Director, 10%+ Owner |
RPTX | Repare Therapeutics Inc. | May 21, 2021 | 3 | -$11.3M | 4 | May 24, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 21, 2021 | 2 | -$321K | 4 | May 24, 2021 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | May 18, 2021 | 8 | -$1.61M | 4 | May 20, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 18, 2021 | 3 | -$982K | 4 | May 20, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 13, 2021 | 3 | -$329K | 4 | May 17, 2021 | 10%+ Owner |
HARP | Harpoon Therapeutics, Inc. | May 10, 2021 | 5 | -$1.44M | 4 | May 12, 2021 | 10%+ Owner |